Xvivo Perfusion AB (publ)
XVIPY
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.78B
Close$
Share Statistics
| Market cap | $6.78 Billion |
|---|---|
| Enterprise Value | $6.60 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.19 |
| Beta | 1.78 |
| Outstanding Shares | 125,997,880 |
Return
| Return on Equity | 4.03% |
|---|---|
| Return on Assets | 3.51% |
| Return on Invested Capital | 4.84% |
Valuation & Multiples
| P/E Ratio | 76.16 |
|---|---|
| PEG | 8.14 |
| Price to Sales | 0.79 |
| Price to Book Ratio | 0.32 |
| Enterprise Value to Revenue | 7.37 |
| Enterprise Value to EBIT | 58.39 |
| Enterprise Value to Net Income | 74 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 14, 2026
EPS Estimate
$0.08
Average shareholder expectationRevenue Estimate
$24.44 M
Average shareholder expectationNext Earnings Call
Expected Date
October 22, 2026
EPS Estimate
$0.80
Average shareholder expectationRevenue Estimate
$237.57 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Xvivo Perfusion AB (publ)
210 employees
CEO: Christoffer Rosenblad Xvivo Perfusion AB (publ) is a specialized medtech company creating advanced technologies for the preservation and perfusion of organs, tissues, and cells, vital for successful transplantation. Founded in 1998 and headquartered in Gothen...